Medical Condition News

RSS

Physicians stimulate patients' medial forebrain bundles to reduce major depression

Researchers from the Bonn University Hospital implanted pacemaker electrodes into the medial forebrain bundle in the brains of patients suffering from major depression with amazing results: In six out of seven patients, symptoms improved both considerably and rapidly.

10 Apr 2013

Non-invasive battery recharger system for electronic implants

Ant-nio Abreu, a Sustainable Energy Systems PhD Student under the MIT Portugal Program, currently developing research work at LNEG (Laborat-rio Nacional de Energia e Geologia I.P.) has developed a non-invasive battery recharger system for electronic implants that allows a longer life for the internal implantable devices in the human body such as, pacemakers, defibrillators, electric heart, delaying considerable the usual customary surgery intervention for replacement.

10 Apr 2013

Researchers evaluate Pexa-Vec to slow progression of liver cancer

As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.

10 Apr 2013

Study finds Google searches for information about mental illnesses, problems follow seasonal patterns

A new study published in the May issue of the American Journal of Preventive Medicine finds that Google searches for information across all major mental illnesses and problems followed seasonal patterns, suggesting mental illness may be more strongly linked with seasonal patterns than previously thought.

10 Apr 2013

Lynch syndrome and cancer risk: an interview with Prof. Ellen Kampman, Wageningen University

Lynch syndrome is one of the inherited cancer syndromes characterized by the development of colorectal cancer, endometrial cancer and other cancers at an early age.

10 Apr 2013

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

10 Apr 2013

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

The Jeffrey Epstein VI Foundation, a science foundation based in New York City, has helped finance the first mathematical model of how human cancer cells evolve, and more specifically, how they evolve to become immune to inhibitor drug therapy, a popular alternative to chemotherapy.

10 Apr 2013

REVEAL trial: VASCAZEN meets primary endpoint

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, is pleased to announce that VASCAZEN met its primary endpoint in the REVEAL trial.

10 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

State roundup: Ga. smoker surcharge could be working; States clamp down on early deliveries; Calif. groups want Medi-Cal transition pause over coverage concerns

State officials say the number of Georgians in the state employee health plan paying $80 more a month in insurance premiums due to smoking has dropped by 44 percent over the past six years.

10 Apr 2013

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.

10 Apr 2013

Cognoptix provides update on multi-site clinical trial of SAPPHIRE II eye test

Cognoptix announced today that it has reached the halfway point in a multi-site clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer's disease patients via a beta amyloid ("Ab") signature in their eyes.

10 Apr 2013

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri.

10 Apr 2013

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.

10 Apr 2013

Findings could help develop new ways to predict risks of tobacco-associated cancers

Believe it or not, while researchers have explored which genes are mutated in each type of tobacco-associated cancer, until now no one had thought to look across these types for common genes that might predict patient outcomes. Results presented at the AACR Annual Meeting 2013 show that in lung and bladder cancers, genes related to the regulation of the cell cycle are associated with poor patient outcomes.

10 Apr 2013

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Multiple genes strongly contribute to risk for schizophrenia

Multiple genes contribute to risk for schizophrenia and appear to function in pathways related to transmission of signals in the brain and immunity, according to an international study led by Virginia Commonwealth University School of Pharmacy researchers.

10 Apr 2013

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed.

10 Apr 2013

Medical Condition News

Physicians stimulate patients' medial forebrain bundles to reduce major depression

Non-invasive battery recharger system for electronic implants

Researchers evaluate Pexa-Vec to slow progression of liver cancer

Study finds Google searches for information about mental illnesses, problems follow seasonal patterns

Lynch syndrome and cancer risk: an interview with Prof. Ellen Kampman, Wageningen University

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

REVEAL trial: VASCAZEN meets primary endpoint

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

State roundup: Ga. smoker surcharge could be working; States clamp down on early deliveries; Calif. groups want Medi-Cal transition pause over coverage concerns

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

Cognoptix provides update on multi-site clinical trial of SAPPHIRE II eye test

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Findings could help develop new ways to predict risks of tobacco-associated cancers

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Multiple genes strongly contribute to risk for schizophrenia

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News